The pharmaceutical industry is approaching one of the most significant commercial shifts in its history. Drugs generating around $300 billion in annual revenue stand to lose market exclusivity by 2030, roughly a sixth of the entire industry’s overall revenue, according to an Evaluate report. For branded manufacturers, this patent cliff is a challenge to plan around. For generics manufacturers, it’s the largest pipeline of opportunity in a generation.
This year marked the start of a particularly pronounced cliff, with key patents set to expire. The drugs involved are not peripheral products; they include some of the world’s best-selling medicines across oncology, immunology, cardiovascular disease and beyond.
The opportunity is real, but the window is narrow
This shift is expected to open a significant opportunity for generic and biosimilar manufacturers between 2025 and 2030. But acting on it requires preparation well in advance. Biosimilar development timelines are long, and decisions made now determine who is positioned when these products are open to competition.
Historical data show branded revenues can decline by 80-90% within just 12 to 18 months of generic or biosimilar entry, which means the commercial benefits go disproportionately to those who move early.
Where should you focus?
The scale of the opportunity doesn’t make the decisions easier. For a generics manufacturer, the more useful questions are specific: which therapeutic areas align with your existing manufacturing capabilities? Where does the UK NHS carry the highest unmet volume demand? What does the prescribing landscape look like – and where are switch programmes already active?
These aren’t questions that can be answered from market reports alone. They require live, granular data on prescribing trends, competitor activity and supply dynamics across the UK market.
Where Pharmly comes in
The Pharmly platform gives manufacturers a real-time view of the UK market – tracking where demand is growing, where healthcare providers are overspending, and where gaps exist that align with a manufacturer’s portfolio capabilities.
For commercial directors thinking about portfolio strategy and acquisition decisions ahead of the patent cliff, Pharmly provides the intelligence to identify the right opportunities – and the confidence to act on them.
To find out more or book a demo, please contact us at info@analytichealth.co.uk.